Literature DB >> 8276258

Multistep evolution of B-cell-derived tumors in humans and rodents.

G Klein1.   

Abstract

At least three genetic changes are known to contribute to the genesis of Burkitt's lymphoma (BL): the Ig/myc translocation, the presence of Epstein-Barr virus (EBV) in the vast majority of the endemic and a minority of sporadic tumors, and a p53 mutation, present in approximately 60% of the BL-derived lines. Activation of c-myc by juxtaposition to Ig sequences is a universal common denominator in endemic and sporadic EBV positive and negative BLs. It acts by preventing the cell from leaving the cycling compartment and by facilitating immune escape. EBV probably acts by expanding the target cell population at risk and prolonging its life span. This, together with the malaria co-factor, would increase the risk of the translocation accident. The p53 mutation may be essential for the continued growth of the tumors where it occurs, since introduction of wild-type p53 leads to their apoptotic death.

Entities:  

Mesh:

Year:  1993        PMID: 8276258     DOI: 10.1016/0378-1119(93)90065-b

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  3 in total

1.  Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease.

Authors:  T Goossens; U Klein; R Küppers
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

2.  Deregulated expression of c-Myc in a translocation-negative plasmacytoma on extrachromosomal elements that carry IgH and myc genes.

Authors:  F Wiener; T I Kuschak; S Ohno; S Mai
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

3.  Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.

Authors:  Megan J Bywater; Gretchen Poortinga; Elaine Sanij; Nadine Hein; Abigail Peck; Carleen Cullinane; Meaghan Wall; Leonie Cluse; Denis Drygin; Kenna Anderes; Nanni Huser; Chris Proffitt; Joshua Bliesath; Mustapha Haddach; Michael K Schwaebe; David M Ryckman; William G Rice; Clemens Schmitt; Scott W Lowe; Ricky W Johnstone; Richard B Pearson; Grant A McArthur; Ross D Hannan
Journal:  Cancer Cell       Date:  2012-07-10       Impact factor: 31.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.